ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Sangeeta Goswami; Yulong Chen; Swetha Anandhan; Péter M. Szabó; Sreyashi Basu; Jorge Blando; Wenbin Liu; Jan Zhang; Seanu Meena Natarajan; Liangwen Xiong; Baoxiang Guan; Shalini S. Yadav; Abdel Saci; James P. Allison; Matthew D. Galsky; Padmanee Sharma

doi:10.1126/scitranslmed.abc4220

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

著者: Sangeeta Goswami, Yulong Chen, Swetha Anandhan, Péter M. Szabó, Sreyashi Basu, Jorge Blando, Wenbin Liu, Jan Zhang, Seanu Meena Natarajan, Liangwen Xiong, Baoxiang Guan, Shalini S. Yadav, Abdel Saci, James P. Allison, Matthew D. Galsky, Padmanee Sharma - Science Translational Medicine 2020 被引用: 128

mutation as a combination biomarker in predicting response to ICT in CheckMate275 and IMvigor210. Combination of the two biomarkers in baseline tumor tissues suggested improved OS compared to either single biomarker. Cumulatively, this study revealed that the combination of CXCL13 plus ARID1A may improve prediction capability for patients receiving ICT.